NDA 020430 · Aspen Global INC
Orgaran
Danaparoid Sodium · Injection
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Jun 26, 2001 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Dec 24, 1996
Approved uses
2
Original approval plus efficacy supplements
Registered trials
1
1 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 26, 2001 Supplement 3 · Efficacy ReviewLabelLetter
- Dec 24, 1996 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
- ORGARAN · DANAPAROID SODIUM 750 UNITS/0.6ML · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Danaparoid" as an intervention, any sponsor and status, largest first.
- Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs ArgatrobanPivotal-lookingTerminated
Aspen Global IncorporatedIndustry
NCT03809481 · 7 participants · Start May 16, 2019 · Primary completion Jun 10, 2022
Drug: Danaparoid Sodium; Argatroban · For: Heparin-induced Thrombocytopenia
Sites: Gainesville, Florida; Minneapolis, Minnesota; Durham, North Carolina · 35 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Anticoagulation for people receiving long-term haemodialysis.
Natale P, Palmer SC, Ruospo M, et al. · Cochrane Database Syst Rev 2024 · Meta-Analysis, Systematic Review
- Orgaran in heparin-induced thrombocytopenia.
Chong BH, Magnani HN · Haemostasis 1992 · Clinical Trial, Multicenter Study
- Orgaran in the prevention of deep vein thrombosis in stroke patients.
Turpie AG · Haemostasis 1992 · Clinical Trial, Comparative Study
- Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture.
Gent M, Hirsh J, Ginsberg JS, et al. · Circulation 1996 · Clinical Trial, Comparative Study
- On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
Schenk JF, Pindur G, Stephan B, et al. · Clin Appl Thromb Hemost 2003 · Clinical Trial, Controlled Clinical Trial
- Heparin-induced Thrombocytopenia in Pediatrics Following Cardiopulmonary Bypass.
Yuan SM · J Coll Physicians Surg Pak 2019 · Meta-Analysis
Sponsor: Aspen Global INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.